{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:48:25Z","timestamp":1784638105153,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014130","name":"Intarcia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021096","name":"George Institute for Global Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ahj.2018.10.010","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T18:16:58Z","timestamp":1541614618000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial"],"prefix":"10.1016","volume":"208","author":[{"given":"Claes","family":"Held","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.H.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Heldestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ahj.2018.10.010_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1740774515601437","article-title":"Alignment of site versus adjudication committee-based diagnosis with patient outcomes: insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial","volume":"13","author":"Sepehrvand","year":"2016","journal-title":"Clin Trials"},{"issue":"1","key":"10.1016\/j.ahj.2018.10.010_bb0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1740774507087972","article-title":"Do we need to adjudicate major clinical events?","volume":"5","author":"Granger","year":"2008","journal-title":"Clin Trials"},{"issue":"4","key":"10.1016\/j.ahj.2018.10.010_bb0015","first-page":"187","article-title":"Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study","volume":"2","author":"Mahaffey","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"15","key":"10.1016\/j.ahj.2018.10.010_bb0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2014.01.038","article-title":"Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"63","author":"Mahaffey","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2018.10.010_bb0025","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.4244\/EIJ-D-18-00131","article-title":"Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial","volume":"14","author":"Kosmidou","year":"2018","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ahj.2018.10.010_bb0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1161\/CIRCULATIONAHA.111.061663","volume":"125","author":"Damman","year":"2011","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ahj.2018.10.010_bb0035","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/eurheartj\/ehv584","article-title":"Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication","volume":"37","author":"Kikkert","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.ahj.2018.10.010_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2018.10.010_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ahj.2018.10.010_bb0050","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","article-title":"Darapladib for preventing ischemic events in stable coronary heart disease","volume":"370","author":"Stability Investigators","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2018.10.010_bb0055","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2010.07.006","article-title":"Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease","volume":"160","author":"White","year":"2010","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.ahj.2018.10.010_bb0060","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","article-title":"Third universal definition of myocardial infarction","volume":"33","author":"Thygesen","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2018.10.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002334","article-title":"Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial","volume":"3","author":"Bolland","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ahj.2018.10.010_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003114","article-title":"Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy","volume":"9","author":"Popma","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.ahj.2018.10.010_bb0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.05.2138","article-title":"A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes","volume":"122","author":"Frederich","year":"2010","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.ahj.2018.10.010_bb0080","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.chest.2016.06.031","article-title":"The inaccuracy of patient recall for COPD exacerbation rate estimation and its implications: results from central adjudication","volume":"150","author":"Frei","year":"2016","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ahj.2018.10.010_bb0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ahj.2013.12.032","article-title":"Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial","volume":"168","author":"Kjoller","year":"2014","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2018.10.010_bb0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ahj.2014.11.003","article-title":"Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium","volume":"169","author":"Seltzer","year":"2015","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318303065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:49Z","timestamp":1762077409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318303065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":18,"alternative-id":["S0002870318303065"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.10.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}